Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.
Product Profiles: Melanoma - Novel combination therapies will increase                        competition for marketed dru...
The limited treatment options in the adjuvant setting will allow the pipeline drugs targeting thispatient population to fa...
Drug profileDevelopment overviewSWOT analysisProduct positioningClinical and commercial attractivenessOther drugsDTIC-Dome...
Drug overviewDrug profileDevelopment overviewSWOT analysisSatisfaction of unmet needsClinical and commercial attractivenes...
Satisfaction of unmet needsClinical and commercial attractivenessPOL-103A (Polynoma/CK Life Sciences)Drug overviewDrug pro...
List of TablesTable: Key marketed drugs for melanoma, 2012Table: Key pipeline drugs for melanoma, 2012Table: Yervoy – drug...
Table: Clinical development of Abraxane in melanoma, 2012Table: Summary of Phase II clinical trial data for Abraxane in me...
Figure: Datamonitors drug assessment summary of Yervoy for melanoma, 2012Figure: Zelboraf’s SWOT analysis for melanoma, 20...
Figure: Datamonitors drug assessment summary of masitinib for melanoma, 2012Figure: The PharmaVitae ExplorerBrowse more Re...
Upcoming SlideShare
Loading in …5
×

Product profiles melanoma novel combination therapies will increase competition for marketed drugs

517 views

Published on

Analysis of marketed melanoma drugs – development history, key clinical trial data, and assessment of clinical and commercial attractiveness
Analysis of marketed and pipeline drugs in comparison to current standard of care
In-depth analysis of late-stage pipeline drugs – development overview, SWOT analysis, and assessment of clinical and commercial attractiveness
Discussion and assessment of pipeline drugs’ ability to meet unmet needs in treatment of melanoma

Published in: Business, Health & Medicine
  • Be the first to comment

  • Be the first to like this

Product profiles melanoma novel combination therapies will increase competition for marketed drugs

  1. 1. Product Profiles: Melanoma - Novel combination therapies will increase competition for marketed drugsThe melanoma market has seen an increase in developer attention following recent breakthroughs.The identification of the role of BRAF mutations has revolutionized the treatment of melanoma, butwith drug resistance a problem there is an opportunity for developers to move into this market.Novel combination therapies and immunotherapies are now poised to compete with the currentmarketed drugs.Buy Your Copy of Report: http://www.reportsnreports.com/reports/179867-product-profiles-melanoma-novel-combination-therapies-will-increase-competition-for-marketed-drugs.htmlReport Details:Published: July 2012Price Single User License: US $ 3800 Price Corporate User License: US $ 9500Features and benefitsAnalysis of marketed melanoma drugs – development history, key clinical trial data, andassessment of clinical and commercial attractivenessAnalysis of marketed and pipeline drugs in comparison to current standard of careIn-depth analysis of late-stage pipeline drugs – development overview, SWOT analysis, andassessment of clinical and commercial attractivenessDiscussion and assessment of pipeline drugs’ ability to meet unmet needs in treatment ofmelanomaHighlightsYervoy and Zelboraf’s high costs have generated significant commercial reward, but have limiteduptake of the drugs in more cost-conservative markets. However, where funded they remain thestandard of care due to the lack of alternative treatments.The combination of pipeline BRAF inhibitor dabrafenib and MEK inhibitor trametinib is thought tobe the biggest threat to the current marketed therapies. The potential of this combination therapyto overcome resistance to BRAF inhibitor monotherapy could allow it to compete strongly in thissetting and take market share from Zelboraf.
  2. 2. The limited treatment options in the adjuvant setting will allow the pipeline drugs targeting thispatient population to face fewer barriers to market entry. There are currently two melanomavaccines in development in this setting.Your key questions answeredIdentify the market leaders in this competitive indication.Compare and assess current late-stage pipeline drugs according to market positioning, commercialpotential and clinical efficacy.Understand how pipeline drugs will be used with current therapies and how the market is accessedthrough less competitive treatment settingsTable of contentsOVERVIEWCatalystSummaryEXECUTIVE SUMMARYStrategic scoping and focusDatamonitor key findingsPRODUCT OVERVIEWKey marketed and pipeline productsDatamonitor’s assessment summaryMARKETED PRODUCT PROFILESYervoy (ipilimumab; Bristol-Myers Squibb)Drug profileDevelopment overviewSWOT analysisProduct positioningClinical and commercial attractivenessZelboraf (vemurafenib; Roche/Daiichi Sankyo)
  3. 3. Drug profileDevelopment overviewSWOT analysisProduct positioningClinical and commercial attractivenessOther drugsDTIC-Dome (dacarbazine; Bayer) and generic dacarbazineTemodar (temozolomide; Merck & Co.)Interleukin-2PIPELINE PRODUCT PROFILESDabrafenib (GSK-2118436; GlaxoSmithKline)Drug overviewDrug profileDevelopment overviewSWOT analysisSatisfaction of unmet needsClinical and commercial attractivenessTrametinib (GSK-1120212; GlaxoSmithKline)Drug overviewDrug profileDevelopment overviewSWOT analysisSatisfaction of unmet needsClinical and commercial attractivenessAbraxane (albumin-bound paclitaxel; Celgene)
  4. 4. Drug overviewDrug profileDevelopment overviewSWOT analysisSatisfaction of unmet needsClinical and commercial attractivenessAllovectin-7 (velimogene aliplasmid; Vical)Drug overviewDrug profileDevelopment overviewSWOT analysisSatisfaction of unmet needsClinical and commercial attractivenessMAGE-A3 ASCI (astuprotimut-r; GlaxoSmithKline)Drug overviewDrug profileDevelopment overviewSWOT analysisSatisfaction of unmet needsClinical and commercial attractivenessOncoVEX GM-CSF (talimogene laherparepvec; Amgen)Drug overviewDrug profileDevelopment overviewSWOT analysis
  5. 5. Satisfaction of unmet needsClinical and commercial attractivenessPOL-103A (Polynoma/CK Life Sciences)Drug overviewDrug profileDevelopment overviewSWOT analysisSatisfaction of unmet needsClinical and commercial attractivenessMasitinib (AB-1010; AB Science)Drug overviewDrug profileDevelopment overviewSWOT analysisSatisfaction of unmet needsClinical and commercial attractivenessBIBLIOGRAPHYJournal papersWebsitesDatamonitor reportsAPPENDIXMarket definitionPharmaVitae Explorer databaseContributing expertsReport methodology
  6. 6. List of TablesTable: Key marketed drugs for melanoma, 2012Table: Key pipeline drugs for melanoma, 2012Table: Yervoy – drug profile, 2012Table: Overview of major melanoma approvals for YervoyTable: Overview of pivotal trial data for Yervoy in melanoma, 2012Table: Datamonitor drug assessment summary of Yervoy for melanoma, 2012Table: Zelboraf – drug profile, 2012Table: Overview of major melanoma approvals for ZelborafTable: Overview of pivotal trial data for Zelboraf in melanoma, 2012Table: Datamonitor drug assessment summary of Zelboraf for melanoma, 2012Table: Dacarbazine – drug profile, 2012Table: Temodar – drug profile, 2012Table: Interleukin-2 – drug profile, 2012Table: Dabrafenib – drug profile, 2012Table: Clinical development of dabrafenib in melanoma, 2012Table: Summary of Phase II clinical trial data for dabrafenib in melanomaTable: Ability of dabrafenib to meet unmet needs in melanoma, 2012Table: Datamonitor drug assessment summary of dabrafenib for melanoma, 2012Table: Trametinib – drug profile, 2012Table: Clinical development of trametinib in melanoma, 2012Table: Summary of Phase II clinical trial data for trametinib in melanomaTable: Ability of trametinib to meet unmet needs in melanoma, 2012Table: Datamonitor drug assessment summary of trametinib for melanoma, 2012Table: Abraxane – drug profile, 2012
  7. 7. Table: Clinical development of Abraxane in melanoma, 2012Table: Summary of Phase II clinical trial data for Abraxane in melanomaTable: Ability of Abraxane to meet unmet needs in melanoma, 2012Table: Datamonitor drug assessment summary of Abraxane for melanoma, 2012Table: Allovectin-7 – drug profile, 2012Table: Clinical development of Allovectin-7 in melanoma, 2010Table: Ability of Allovectin-7 to meet unmet needs in melanoma, 2012Table: Datamonitor drug assessment summary of Allovectin-7 for melanoma, 2012Table: MAGE-A3 ASCI – drug profile, 2012Table: Clinical development of MAGE-A3 ASCI in melanoma, 2012Table: Datamonitor drug assessment summary of MAGE-A3 ASCI for melanoma, 2012Table: OncoVEX GM-CSF – drug profile, 2012Table: Clinical development of OncoVEX GM-CSF in melanoma, 2012Table: Ability of OncoVEX GM-CSF to meet unmet needs in first-line metastatic melanoma, 2012Table: Datamonitor drug assessment summary of OncoVEX GM-CSF for melanoma, 2012Table: POL-103A – drug profile, 2012Table: Clinical development of POL-103A, 2012Table: Datamonitor drug assessment summary of POL-103A for melanoma, 2012Table: Masitinib – drug profile, 2012Table: Clinical development of masitinib, 2012Table: Datamonitor drug assessment summary of masitinib for melanoma, 2012Table: Summary of therapeutic classes in melanoma by ATC code, 2012List of FiguresFigure: Datamonitors drug assessment summary of key marketed and pipeline drugs formelanoma, 2012Figure: Yervoy’s SWOT analysis for melanoma, 2012
  8. 8. Figure: Datamonitors drug assessment summary of Yervoy for melanoma, 2012Figure: Zelboraf’s SWOT analysis for melanoma, 2012Figure: Datamonitors drug assessment summary of Zelboraf for melanoma, 2012Figure: Phase III results for first-line dabrafenib in metastatic melanomaFigure: Dabrafenib’s SWOT analysis for melanoma, 2012Figure: Datamonitors drug assessment summary of dabrafenib for melanoma, 2012Figure: Phase III results for first- or second-line trametinib in metastatic melanomaFigure: Trametinib’s SWOT analysis for melanoma, 2012Figure: Datamonitors drug assessment summary of trametinib for melanoma, 2012Figure: Phase II results for first-line and second-line Abraxane in metastatic melanomaFigure: Abraxane’s SWOT analysis for melanoma, 2012Figure: Datamonitors drug assessment summary of Abraxane for melanoma, 2012Figure: Phase II results for second-line Allovectin-7 in metastatic melanoma, 2010Figure: Allovectin-7’s SWOT analysis for melanoma, 2012Figure: Datamonitors drug assessment summary of Allovectin-7 for melanoma, 2012Figure: Phase II results for MAGE-A3 ASCI in combination with two different adjuvant systemsFigure: MAGE-A3 ASCI’s SWOT analysis for melanoma, 2012Figure: Datamonitors drug assessment summary of MAGE-A3 ASCI for melanoma, 2012Figure: Phase II results for second-line OncoVEX GM-CSF monotherapy for unresectable Stage IIIcand IV melanomaFigure: OncoVEX GM-CSF’s SWOT analysis for melanoma, 2012Figure: Datamonitors drug assessment summary of OncoVEX GM-CSF for melanoma, 2012Figure: Phase II results for adjuvant POL-103A in melanoma, 2012Figure: POL-103A’s SWOT analysis for melanoma, 2011Figure: Datamonitors drug assessment summary of POL-103A for melanoma, 2012Figure: Masitinib’s SWOT analysis for melanoma, 2012
  9. 9. Figure: Datamonitors drug assessment summary of masitinib for melanoma, 2012Figure: The PharmaVitae ExplorerBrowse more Research Reports @ http://www.reportsnreports.com/market-research/pharmaceuticals/Contact Us:TX, Dallas North - Dominion Plaza,17304, Preston Road,Suite 800, Dallas 75252.+ 1 888 391 5441Email: sales@reportsandreports.comConnect With Us:

×